Amphotericin B

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Amphotericin B
   1. Pharmacist Assessment Report
   2. Amphotericin B: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Amphotericin B: Known uses and market status in Australia

Summary

The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Amphotericin B, so there is currently no new predicted indication. The drug’s own recorded uses (15 in total) are listed below. They come from existing records and are not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	15
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
None	None

Related to an approved indication (same disease category)

Indication	Approved category
None	None

Relations recorded in the knowledge graph (no approval found)

Indication
acne
actinomycetales infectious disease
actinomycosis
acute gonococcal cervicitis
anthrax infection
aspergillosis
black piedra
blastomycosis
bronchitis
brucellosis
candidemia
candidiasis
cat-scratch disease
chancroid
coccidioidomycosis

Australia Market Information

Licence	Product	Dosage form	Status
2931G	Fungilin	Lozenge 10 mg	Valid

Safety Considerations

• Contraindications flagged in the knowledge graph (not label text): kidney disease, pyoureter, liver disease, gallbladder disease, potassium deficiency, Clostridium difficile colitis, perinatal necrotising enterocolitis.
• Drug interactions: 100 interactions were identified. Those classed as Major include foscarnet, gallium nitrate, amiodarone and arsenic trioxide. Moderate interactions include zidovudine, acetazolamide, hydrocortisone, furosemide, hydrochlorothiazide, ganciclovir and amikacin. Corticosteroids and diuretics are of particular note, given the risk of hypokalaemia.

Please also refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---